Search

Your search keyword '"Mepolizumab"' showing total 2,959 results

Search Constraints

Start Over You searched for: Descriptor "Mepolizumab" Remove constraint Descriptor: "Mepolizumab"
2,959 results on '"Mepolizumab"'

Search Results

1. Targeting the IL‐5 pathway in eosinophilic asthma: A comparison of anti‐IL‐5 versus anti‐IL‐5 receptor agents.

2. Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma.

3. Three cases of relapsed eosinophilic sinusitis without eosinophilia during mepolizumab maintenance therapy for eosinophilic granulomatosis with polyangiitis.

4. Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program.

5. Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST).

6. Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study.

7. Achieving clinical remission in asthma with mepolizumab: a subanalysis on vitamin D as a predictor of response.

8. Spending, utilization, and coverage for chronic rhinosinusitis with nasal polyposis therapies among Medicare Advantage beneficiaries.

9. Comparison of the Efficacy of Omalizumab and Mepolizumab in Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease.

10. Anti–IL-4R versus anti–IL-5/5R after anti–IL-5/5R failure in asthma: An emulated target trial.

11. A comparison of the impact of anti-IL5/5r therapies in allergic versus non-allergic patients with severe eosinophilic asthma in a real-life setting.

12. Treatment of Severe Asthma: Case Report of Fast Action of Mepolizumab in a Patient with Recent SARS-CoV-2 Infection.

13. Combination effect of Mepolizumab and Endobronchial Watanabe Spigot (EWS) in drug‐induced eosinophilic pneumonia complicated by refractory pneumothorax.

14. Trends in prevalence, treatment use, and disease burden in patients with eosinophilic granulomatosis with polyangiitis in Japan: Real-world database analysis.

17. Biologic Therapies: Targeting Severe Asthma at the Molecular Level.

18. Reduced Sense of Smell in Patients with Severe Chronic Rhinosinusitis and its Implications for Diagnosis and Management: A Narrative Review.

19. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.

20. Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series

21. Monocentric study of IL-5 monoclonal antibody induction therapy for eosinophilic granulomatosis with polyangiitis

22. Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience.

23. Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways.

24. Biologics in T2 Severe Asthma: Unveiling Different Effectiveness by Real-World Indirect Comparison.

25. Anti-IL-5 and anti-IL-5R biologics for severe asthma. Are there any differences in their effects?

26. Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience.

27. SingleNucleotide Polymorphisms as Biomarkers of Mepolizumab and Benralizumab Treatment Response in Severe Eosinophilic Asthma.

28. Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity.

29. Mepolizumab in Severe Pediatric Asthma: Certainties and Doubts through a Single-Center Experience and Review of the Literature.

30. Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC).

31. A case of subarachnoid haemorrhage associated with MPO-ANCA-positive eosinophilic granulomatosis with polyangiitis, successfully treated with glucocorticoid, cyclophosphamide, and mepolizumab.

32. Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma.

33. The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma.

34. Eosinophilic granulomatosis with polyangiitis developed during treatment with benralizmab for severe asthma: A case report and literature review.

35. Monocentric study of IL-5 monoclonal antibody induction therapy for eosinophilic granulomatosis with polyangiitis.

36. Real‐World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps.

37. Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases.

38. Evaluation of multiple-flows exhaled nitric oxide and its clinical significance in severe asthmatic patients treated with biologics: a prospective real-life study.

39. Real-Life Evidence of Mepolizumab Treatment in Chronic Rhinosinusitis with Nasal Polyps: A Multicentric Study.

40. The role of ACT score in mepolizumab discontinuation.

41. A tailored approach to refractory severe Mepolizumab-associated headache: a case study.

42. The clinical effectiveness of mepolizumab treatment in severe eosinophilic asthma; outcomes from four years cohort evaluation.

43. Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP.

44. Peak nasal inspiratory flow assessment of polyp size and response from SYNAPSE

45. Case Report: Dual monoclonal antibody therapy in chronic rhinosinusitis with nasal polyps and severe eosinophilic asthma—a proteome analysis

46. Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database

47. Combination effect of Mepolizumab and Endobronchial Watanabe Spigot (EWS) in drug‐induced eosinophilic pneumonia complicated by refractory pneumothorax

48. Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super‐Response and Remission With Mepolizumab.

Catalog

Books, media, physical & digital resources